Skip to content

Development and Evaluation of an MRI Data-Driven Multidimensional Decision System for Prognostic Prediction in Central Nervous System Lymphoma

Development and Evaluation of an MRI Data-Driven Multidimensional Decision System for Prognostic Prediction in Central Nervous System Lymphoma

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2600129190
Enrollment
Unknown
Registered
2026-07-31
Start date
2026-08-01
Completion date
Unknown
Last updated
2026-08-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Central nervous system lymphoma, including primary and secondary central nervous system lymphoma

Interventions

Central Nervous System Lymphoma Observational Cohort:None

Sponsors

Tongji Hospital of Tongji University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 90 Years

Inclusion criteria

Inclusion criteria: 1.Patients aged 18–90 years, regardless of sex; 2.A confirmed diagnosis of central nervous system lymphoma, including primary or secondary central nervous system lymphoma, based on histopathology, cerebrospinal fluid cytology, or flow cytometry; 3.Availability of analyzable multiparametric brain MRI data, including the principal sequences of T1-weighted imaging, T2-weighted imaging, FLAIR, diffusion-weighted imaging, and contrast-enhanced T1-weighted imaging; 4.Availability of relevant clinical, pathological, laboratory, treatment, and follow-up data; 5.For patients included in the ctDNA analysis, availability of eligible plasma and/or cerebrospinal fluid ctDNA data;

Exclusion criteria

Exclusion criteria: 1.Poor-quality MRI images, substantial motion artifacts, or absence of essential MRI sequences that preclude lesion assessment or imaging-feature extraction; 2.Substantial missing clinical, pathological, treatment, or follow-up information that prevents determination of the main study outcomes; 3.Coexisting primary malignant tumors of the central nervous system that may interfere with imaging assessment or outcome determination; 4.Contraindications to MRI that prevent prospectively enrolled participants from completing the required imaging examinations; 5.Refusal to participate, withdrawal of informed consent, or inability to complete follow-up during the prospective study; 6.Other conditions considered unsuitable for inclusion by the investigators;

Design outcomes

Primary

MeasureTime frame
Progression-free survival;

Secondary

MeasureTime frame
Treatment response of central nervous system lymphoma;

Countries

China

Contacts

Public ContactAijun Shen

Tongji Hospital of Tongji University

sajdzyx@126.com+86 21 66111206

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Aug 10, 2026